PBF-999
Prader-Willi Syndrome
Phase 1Active
Key Facts
About Palo BioFarma
Palobiofarma is a private, clinical-stage biotech company targeting rare diseases through selective adenosine receptor modulation. Its lead candidate, PBF-999, is in clinical development for Prader-Willi Syndrome, and the company has recently completed a research project on a dual A2A/H3 antagonist for Parkinson's disease. The company employs a lean, virtual R&D model, focusing internal expertise on drug design and chemistry while outsourcing later-stage preclinical work to CROs and academic partners. Its vision is to bring the first marketed selective adenosine receptor modulator to patients.
View full company profileTherapeutic Areas
Other Prader-Willi Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| NNZ-2591 | Neuren Pharmaceuticals | Phase 2 |
| Sepranolone | Relmada Therapeutics | Phase 2b Planned |